SCHEMBL25755501

SCHEMBL25755501

COc1ccc(NC(=O)c2[nH]c(C)cc2C)cc1S(=O)(=O)Nc1ccc(Br)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.70
KMT2A Q03164 6/20 0.70
LMNA P02545 5/20 0.63
MEN1 O00255 5/20 0.63
SMN1; SMN2 Q16637 4/20 0.63
ALDH1A1 P00352 4/20 0.63
GAA P10253 3/20 0.63
ALOX12 P18054 2/20 0.63
CRHBP P24387 1/20 0.63
CRHR2 Q13324 1/20 0.63
KDM4E B2RXH2 2/20 0.55
NPC1 O15118 1/20 0.55
HTT P42858 1/20 0.55
HPGD P15428 2/20 0.52
HDAC1 Q13547 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
POLB P06746 2/20 0.48
IDH1 O75874 2/20 0.47
TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25753999 0.82 KMT2A (0.79) MAPTKMT2ALMNAMEN1SMN1; SMN2
SCHEMBL25755504 0.80 MAPT (0.82) MAPTKMT2ALMNAMEN1SMN1; SMN2
SCHEMBL23846434 0.80 MAPT (0.62) MAPTKMT2ALMNAMEN1SMN1; SMN2
SCHEMBL25755590 0.78 KMT2A (0.67) MAPTKMT2ALMNAMEN1SMN1; SMN2
SCHEMBL17980878 0.78 KMT2A (0.61) MAPTKMT2ALMNAMEN1SMN1; SMN2
SCHEMBL25755512 0.77 KMT2A (0.62) MAPTKMT2ALMNAMEN1SMN1; SMN2
SCHEMBL25755498 0.77 KMT2A (0.62) MAPTKMT2ALMNAMEN1SMN1; SMN2
SCHEMBL25755514 0.77 KMT2A (0.64) MAPTKMT2ALMNAMEN1SMN1; SMN2
SCHEMBL25755495 0.77 MAPT (0.67) MAPTKMT2ALMNAMEN1SMN1; SMN2
SCHEMBL25757029 0.76 KMT2A (0.67) MAPTKMT2ALMNAMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, TP53BP1 MAPT 89/4885KMT2A 4864/4885LMNA 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.